Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Muscle-Invasive Bladder Carcinoma × Radiotherapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 220 Glioblastoma 181 Breast Neoplasms 181 Lung Neoplasms 177 Head and Neck Neoplasms 158 Prostatic Neoplasms 148 Lymphoma 144 Squamous Cell Carcinoma of Head and Neck 142 Rectal Neoplasms 122 Central Nervous System Neoplasms 111 Esophageal Neoplasms 105 Leukemia 101 Brain Neoplasms 91 Pancreatic Neoplasms 88 Precursor Cell Lymphoblastic Leukemia-Lymphoma 86 Gliosarcoma 81 Lymphoma, Follicular 75 Esophageal Squamous Cell Carcinoma 75 Lymphoma, Large B-Cell, Diffuse 73 Sarcoma 71 Lymphoma, Non-Hodgkin 70 Hodgkin Disease 68 Uterine Cervical Neoplasms 67 Burkitt Lymphoma 63 Neoplasms 59 Leukemia, Lymphocytic, Chronic, B-Cell 59 Colorectal Neoplasms 58 Astrocytoma 56 Lymphoma, Large-Cell, Immunoblastic 54 Glioma 54

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05203913 2024-10-04

CNN-BC

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡